Discover the 2023 Gene Therapy Landscape

A comprehensive analysis of the drug, trial and commercial landscape, including updates from 2023, relevant regulatory announcements, and the future of the Gene Therapy landscape.

Download Here

About the 2023 Landscape Review

The review highlights the growing importance of understanding immunogenicity in gene therapy, considering over 80 withdrawn or suspended trials in the field. The focus on immunogenicity aids in informed vector identification for gene therapy. The use of proprietary vectors, like STRIVE™ and AIM™, is emphasized for efficient downstream processes. In the context of neurological disorders, specifically Duchenne muscular dystrophy, the gene therapy space is rapidly expanding, with a notable increase in assets. A substantial portion of these assets, particularly 78.3%, is in the preclinical stage, primarily targeting neurological, eye, and blood disorders.

AAV vectors remain the dominant delivery system, constituting 53.7% of the gene therapy space, but interest in non-viral vectors, especially LNPs, is on the rise. The past year witnessed significant drug approvals for various disorders, reflecting the field’s progress. Most trials are in phase 1/2, indicating a focus on safety and dosing, but the expectation is for more assets to progress to higher phases in the coming years. Despite a dip in investment between 2020 and 2022, 2023 recorded a notable increase to $85 billion, signaling renewed interest and potential growth in the gene therapy space, driven by recent drug approvals and expanding indications.

You may also be interested in...

Unlock the Future of Advanced Therapies: Insights from the ASGCT 2024 Annual Meeting

Find out more

Beacon Gene Therapy: 2024 ASGCT Annual Meeting Abstracts

Find out more

2023 Gene Therapy Landscape Review

Find out more

The 2023 RNA Landscape Review

Find out more

2023 Cell Therapy Landscape Review

Find out more

2023 Immune Tolerance Landscape Review

Find out more

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.

With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.

Discover more about Beacon

Any questions? Get in touch

Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.





 Get Started